Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 13:16:25.
doi: 10.1186/s12979-019-0164-9. eCollection 2019.

Immunosenescence and human vaccine immune responses

Affiliations
Review

Immunosenescence and human vaccine immune responses

Stephen N Crooke et al. Immun Ageing. .

Abstract

The age-related dysregulation and decline of the immune system-collectively termed "immunosenescence"-has been generally associated with an increased susceptibility to infectious pathogens and poor vaccine responses in older adults. While numerous studies have reported on the clinical outcomes of infected or vaccinated individuals, our understanding of the mechanisms governing the onset of immunosenescence and its effects on adaptive immunity remains incomplete. Age-dependent differences in T and B lymphocyte populations and functions have been well-defined, yet studies that demonstrate direct associations between immune cell function and clinical outcomes in older individuals are lacking. Despite these knowledge gaps, research has progressed in the development of vaccine and adjuvant formulations tailored for older adults in order to boost protective immunity and overcome immunosenescence. In this review, we will discuss the development of vaccines for older adults in light of our current understanding-or lack thereof-of the aging immune system. We highlight the functional changes that are known to occur in the adaptive immune system with age, followed by a discussion of current, clinically relevant pathogens that disproportionately affect older adults and are the central focus of vaccine research efforts for the aging population. We conclude with an outlook on personalized vaccine development for older adults and areas in need of further study in order to improve our fundamental understanding of adaptive immunosenescence.

Keywords: Adaptive immunity; Aging; B cell; Immune response; Immunosenescence; T cell; Vaccination.

PubMed Disclaimer

Conflict of interest statement

Competing interestsDr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., Avianax, Adjuvance, Valneva, Medicago, Sanofi Pasteur, GlaxoSmithKline, Dynavax, and Emergent Biosolutions. Drs. Poland and Ovsyannikova hold three patents related to vaccinia and measles peptide vaccines. Dr. Kennedy holds a patent related to vaccinia peptide vaccines. Dr. Kennedy has received research funding from Merck Research Laboratories to study waning immune responses to mumps vaccine. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Immunological changes associated with aging and adaptive immunosenescence. Specific changes in the T and B cell compartments are known to occur with aging and the onset of immunosenescence. Naïve lymphocyte production, lymphocyte repertoire diversity, and the proliferative and functional capacity of effector lymphocytes all decline with age; similarly, increases in differentiated memory cell populations, lymph node fibrosis, and altered cytokine production all occur. These phenomena have been collectively associated with diminished vaccine responses and an increased susceptibility to viral infectious diseases in older adults. The mechanisms by which immunosenescence operates are not fully understood, and systems biology approaches are currently focused on elucidating these mechanisms in order to inform the rational design of vaccines for older adults

References

    1. Fulop T, Dupuis G, Witkowski JM, Larbi A. The role of Immunosenescence in the development of age-related diseases. Rev Investig Clin. 2016;68(2):84–91. - PubMed
    1. Fuentes E, Fuentes M, Alarcon M, Palomo I. Immune system dysfunction in the elderly. An Acad Bras Cienc. 2017;89(1):285–299. doi: 10.1590/0001-3765201720160487. - DOI - PubMed
    1. Pera Alejandra, Campos Carmen, López Nelson, Hassouneh Fakhri, Alonso Corona, Tarazona Raquel, Solana Rafael. Immunosenescence: Implications for response to infection and vaccination in older people. Maturitas. 2015;82(1):50–55. doi: 10.1016/j.maturitas.2015.05.004. - DOI - PubMed
    1. Nikolich-Zugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2018;19(1):10–19. doi: 10.1038/s41590-017-0006-x. - DOI - PubMed
    1. Nikolich-Zugich J. Aging of the T cell compartment in mice and humans: from no naive expectations to foggy memories. J Immunol. 2014;193(6):2622–2629. doi: 10.4049/jimmunol.1401174. - DOI - PMC - PubMed

LinkOut - more resources